Overview

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Status:
COMPLETED
Trial end date:
2025-02-10
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery. The primary efficacy endpoint is the summed pain intensity difference over 24 hours ( SPID24)
Phase:
PHASE3
Details
Lead Sponsor:
Yangtze River Pharmaceutical Group Co., Ltd.
Treatments:
Meloxicam
Sodium Chloride